Cancer Science

Cover image for Vol. 107 Issue 11

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Yusuke Nakamura

Impact Factor: 3.896

ISI Journal Citation Reports © Ranking: 2015: 62/213 (Oncology)

Online ISSN: 1349-7006

VIEW

  1. 1 - 11
  1. Original Articles

    1. You have full text access to this OnlineOpen article
      CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance

      Hiroyuki Minemura, Kiyoshi Takagi, Ai Sato, Hikaru Takahashi, Yasuhiro Miki, Yukiko Shibahara, Mika Watanabe, Takanori Ishida, Hironobu Sasano and Takashi Suzuki

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/cas.13081

      Thumbnail image of graphical abstract

      This is the first report that examined CITED2 protein in human breast carcinoma. Results of our immunohistochemical study demonstrated that the CITED2 status was an independent worse prognostic factor of the patients, and in vitro studies indicated that CITED2 promoted cell proliferation, migration and chemoresistance in breast carcinoma cells. These results suggest a pivotal role of CITED2 in breast carcinoma, and CITED2 could become an important prognostic marker and therapeutic target to improve clinical outcome of breast cancer patients.

    2. You have full text access to this OnlineOpen article
      Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma

      Akiko Harada, Junji Uchino, Taishi Harada, Noriaki Nakagaki, Junko Hisasue, Masaki Fujita and Koichi Takayama

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/cas.13112

      Thumbnail image of graphical abstract

      Vascular endothelial growth factor plays a pivotal role and is a potential target molecule for new MM therapies. VEGF-CRAd produces oncolytic effects in MM in vitro. VEGF-CRAd offers survival benefits in MPM tumor-bearing mice.

    3. You have full text access to this OnlineOpen article
      Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt/β-catenin signaling pathway

      Issei Egashira, Fumi Takahashi-Yanaga, Risa Nishida, Masaki Arioka, Kazunobu Igawa, Katsuhiko Tomooka, Yoshimichi Nakatsu, Teruhisa Tsuzuki, Yusaku Nakabeppu, Takanari Kitazono and Toshiyuki Sasaguri

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/cas.13106

      Thumbnail image of graphical abstract

      DM-celecoxib suppress the Wnt/bete-catenin signaling pathway. DM-celecoxib inhibited intestinal tumor growth in vivo.

    4. You have full text access to this OnlineOpen article
      A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor

      Yuta Yamada, Ken-ichi Takayama, Tetsuya Fujimura, Daisaku Ashikari, Daisuke Obinata, Satoru Takahashi, Kazuhiro Ikeda, Shigenori Kakutani, Tomohiko Urano, Hiroshi Fukuhara, Yukio Homma and Satoshi Inoue

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/cas.13105

      Thumbnail image of graphical abstract

      Our study suggests that TRIM44 represses apoptosis and promotes cell proliferation and migration, leading to poor prognosis in patients with TGCT via regulating cancer-related genes such as NT5E and CADM1. These findings may shed new light to a new prognostic marker for TGCTs.

    5. You have full text access to this OnlineOpen article
      miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells

      Jing Song and Yue Li

      Version of Record online: 1 DEC 2016 | DOI: 10.1111/cas.13104

      Thumbnail image of graphical abstract

      In summary, our data suggest that CR cells went through EMT partly by way of miR-25-3p downregulation. More importantly, overexpression of miR-25-3p reversed CR-induced EMT and sensitized CR cells to cisplatin by targeting Sema4C. This study indicated that activation of miR-25-3p could be a novel strategy to combat chemotherapy resistance in cervical cancer.

    6. You have full text access to this OnlineOpen article
      Metformin inhibits estrogen-dependent endometrial cancer cell growth by activating the AMPK–FOXO1 signal pathway

      Jingfang Zou, Liangli Hong, Chaohuan Luo, Zhi Li, Yuzhang Zhu, Tianliang Huang, Yongneng Zhang, Huier Yuan, Yaqiu Hu, Tengfei Wen, Wanling Zhuang, Bozhi Cai, Xin Zhang, Jiexiong Huang and Jidong Cheng

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13083

      Thumbnail image of graphical abstract

      Metformin may exert its anti-proliferative effect on EC cells by activating AMPK and thus decreasing phosphorylation of FOXO1 protein, thereby triggering the relocalization of FOXO1 protein from the cytoplasm to the nucleus and resulting in increased FOXO1 activity. This study provide a novel mechanism of anti-neoplastic effect for metformin through the regulation of FOXO1, and suggest that AMPK-FOXO1 pathway may be a therapeutic target to the development of new anti-neoplastic drugs.

    7. You have full text access to this OnlineOpen article
      Establishment of MAGEC2-knockout cells and functional investigation of MAGEC2 in tumor cells

      Jingjing Wang, Xiao Song, Chengli Guo, Ying Wang and Yanhui Yin

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13082

      Thumbnail image of graphical abstract

      We established MAGEC2-knockout A375 melanoma cell lines using the CRISPR/Cas9 system, and subsequently carried out iTRAQ based comparative proteomics analysis to identify the differentially expressed protein profiles associated with MAGEC2 loss. The differentially expressed proteome was evaluated using the Ingenuity Pathways Analysis software, which revealed the molecular pathways that MAGEC2 may be involved in tumorigenesis and cancer development.

    8. You have full text access to this OnlineOpen article
      EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway

      Akifumi Endo, Daisuke Tomizawa, Yuki Aoki, Tomohiro Morio, Shuki Mizutani and Masatoshi Takagi

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13080

      Thumbnail image of graphical abstract

      Novel chimeric fusion gene, EWSR1/ELF5, was identified in a patient with acute myeloid leukemia (AML). EWSR1/ELF5 induced cetllular transformation by attenuating with the p53/p21-dependent pathway.

    9. You have full text access to this OnlineOpen article
      First-line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma

      Yongshun Chen, Jing Yang, Xue Li, Daxuan Hao, Xiaoyuan Wu, Yuanyuan Yang, Chunyu He, Wen Wang and Jianhua Wang

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13079

      Thumbnail image of graphical abstract

      Though our study was limited by the retrospective nature, our analysis has the following strengths: it focuses on a specific histologic subtype of lung cancer, the findings showed that for EGFR-mutated lung adenocarcinoma patients with BM, the combination of EGFR-TKI plus WBRT had (i) higher intracranial objective response rate, (ii) longer time to intracranial progression, but (iii) similar overall survival.

    10. You have full text access to this OnlineOpen article
      Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma

      Dai Maruyama, Hirokazu Nagai, Noriko Fukuhara, Toshiyuki Kitano, Takayuki Ishikawa, Hirohiko Shibayama, Ilseung Choi, Kiyohiko Hatake, Toshiki Uchida, Momoko Nishikori, Tomohiro Kinoshita, Yoshihiro Matsuno, Tomoaki Nishikawa, Satoko Takahara and Kensei Tobinai

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13076

      Thumbnail image of graphical abstract

      The aim of this study was to evaluate the efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory MCL. The orally administered single agent ibrutinib was found to be efficacious with acceptable safety profile in Japanese patients with relapsed or refractory MCL.

    11. You have full text access to this OnlineOpen article
      YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer

      Masafumi Horie, Akira Saito, Mitsuhiro Ohshima, Hiroshi I. Suzuki and Takahide Nagase

      Version of Record online: 25 NOV 2016 | DOI: 10.1111/cas.13078

      Thumbnail image of graphical abstract

      Subtypes of SCLC cell lines defined by expression patterns of transcription factors. Two-dimensional hierarchical clustering of expression levels of 1520 transcription factors in SCLC cell lines.

VIEW

  1. 1 - 11

SEARCH

SEARCH BY CITATION